Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris
Status:
Completed
Trial end date:
2018-10-22
Target enrollment:
Participant gender:
Summary
To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo
when administered topically for the treatment of pruritus associated with psoriasis vulgaris
(PV) and PV itself.